Dongyangguang Pharmaceutical (06887) surged over 6% in the afternoon trading session. As of the time of writing, it was up 6.55%, trading at HKD 46.2 with a turnover of HKD 30.6289 million.
According to Zhitong Finance, Dongyangguang Pharmaceutical (06887) surged over 6% in the afternoon session. As of the time of writing, it was up 6.55%, trading at HKD 46.2 with a turnover of HKD 30.6289 million.
In terms of developments, on January 16, the company's self-developed Class 1 innovative drug Ologlitazon Capsule received approval from the National Medical Products Administration for market launch. It is indicated for use as monotherapy or in combination with metformin to improve glycemic control in adult patients with type 2 diabetes. A relevant representative of Dongyangguang Pharmaceutical stated that the approval of Ologlitazon marks a solid step forward in the company’s efforts toward long-term management of chronic diseases.
Notably, Dongyangguang Pharmaceutical recently announced that the group is further deepening its AI strategy by launching an AI-driven R&D platform tailored for PROTAC mechanisms. This platform achieves a 'dry-to-wet closed loop' from data infrastructure, with data scale and structural granularity significantly surpassing existing public databases. It provides comprehensive and systematic data support for AI-driven rational design of PROTACs, accelerating the rational design and clinical translation of PROTAC lead compounds.
